Physician profile
Khaled Hammoud
NPI 1982806402
$30,477.43
in general payments reported to CMS, 2019-2025
78 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,960 · 2020: $1,583 · 2021: $1,802 · 2022: $2,429 · 2023: $2,848 · 2024: $2,909 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $9,315 · Travel and Lodging: $351 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,016.89 |
| Food and Beverage | $9,315.44 |
| Travel and Lodging | $351.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $12,132.23 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Livanova USA, INC. | $2,005.67 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,965.68 | 2019-2025 | |
| Biogen, INC. | $988.83 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Medtronic USA, INC. | $763.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $699.10 | 2019-2025 | |
| Pfizer INC. | $573.96 | 2019-2025 | |
| Lundbeck LLC | $570.24 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $558.99 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Acadia Pharmaceuticals INC | $508.52 | 2019-2025 | Nuplazid, Daybue |
| Emd Serono, INC. | $506.63 | 2019-2025 | Mavenclad, Mavenclad |
| Jazz Pharmaceuticals INC. | $494.34 | 2019-2025 | Epidiolex, Xywav |
| Teva Pharmaceuticals USA, INC. | $473.53 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $450.39 | 2019-2022 | |
| Csl Behring | $416.36 | 2019-2025 | Hizentra, Kcentra |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Hammoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.